Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 12, 2013, Pages 2827-2834

  Soldan, Anja ^a   Pettigrew, Corinne ^a   Li, Shanshan ^b   Wang, Mei Cheng ^b   Moghekar, Abhay ^a   Selnes, Ola A ^a   Albert, Marilyn ^a   O'Brien, Richard ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Amyloid; Biomarkers; Cerebrospinal fluid; Cognitive reserve; Cohort studies; Mild cognitive impairment; Preclinical Alzheimer's disease; Tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; EDUCATIONAL STATUS; FEMALE; HUMAN; LANGUAGE ABILITY; MALE; MENTAL FUNCTION; PRIORITY JOURNAL; READING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM;

AMYLOID; BIOMARKERS; CEREBROSPINAL FLUID; COGNITIVE RESERVE; COHORT STUDIES; MILD COGNITIVE IMPAIRMENT; PRECLINICAL ALZHEIMER'S DISEASE; TAU;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PROPORTIONAL HAZARDS MODELS; RISK; TAU PROTEINS; TIME FACTORS;

EID: 84884128656     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.06.017     Document Type: Article

References (50)

1. Andel R., Crowe M., Pedersen N.L., Mortimer J., Crimmins E., Johansson B., Gatz M. Complexity of work and risk of Alzheimer's disease: a population-based study of Swedish twins. J.Gerontol. B. Psychol. Sci. Soc. Sci. 2005, 60:251-258.
2. Arenaza-Urquijo E.M., Molinuevo J.L., Sala-Llonch R., Sole-Padulles C., Balasa M., Bosch B., Olives J., Antonell A., Llado A., Sanchez-Valle R., Rami L., Bartres-Faz D. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-beta levels. J.Alzheimers Dis. 2013, 35:715-726.
3. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
4. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Arnold S.E. Education modifies the association of amyloid but not tangles with cognitive function. Neurology 2005, 65:953-955.
5. Bennett D.A., Wilson R.S., Boyle P.A., Buchman A.S., Schneider J.A. Relation of neuropathology to cognition in persons without cognitive impairment. Ann. Neurol. 2012, 72:599-609.
6. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Mendes de Leon C.F., Arnold S.E., Barnes L.L., Bienias J.L. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003, 60:1909-1915.
7. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
8. De Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S., De Deyn P.P., Coart E., Hansson O., Minthon L., Zetterberg H., Blennow K., Shaw L., Trojanowski J.Q. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 2010, 67:949-956.
9. Dumurgier J., Paquet C., Benisty S., Kiffel C., Lidy C., Mouton-Liger F., Chabriat H., Laplanche J.L., Hugon J. Inverse association between CSF Abeta 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory. Neurobiol. Dis. 2010, 40:456-459.
10. Ewers M., Insel P.S., Stern Y., Weiner M.W. Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013, 80:1194-1201.
11. Fitzpatrick A.L., Kuller L.H., Ives D.G., Lopez O.L., Jagust W., Breitner J.C., Jones B., Lyketsos C., Dulberg C. Incidence and prevalence of dementia in the Cardiovascular Health Study. J.Am. Geriatr. Soc. 2004, 52:195-204.
12. Hedden T., Mormino E.C., Amariglio R.E., Younger A.P., Schultz A.P., Becker J.A., Buckner R.L., Johnson K.A., Sperling R.A., Rentz D.M. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J.Neurosci. 2012, 32:16233-16242.
13. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. Anew clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
14. Hulette C.M., Welsh-Bohmer K.A., Murray M.G., Saunders A.M., Mash D.C., McIntyre L.M. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J.Neuropathol. Exp. Neurol. 1998, 57:1168-1174.
15. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
16. Jagust W.J., Mormino E.C. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends. Cogn. Sci. 2011, 15:520-526.
17. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., McDonald W.C., Braak H., Petersen R.C. Neuropathology of cognitively normal elderly. JNeuropathol. Exp. Neurol. 2003, 62:1087-1095.
18. Landau S.M., Marks S.M., Mormino E.C., Rabinovici G.D., Oh H., O'Neil J.P., Wilson R.S., Jagust W.J. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch. Neurol. 2012, 69:623-629.
19. Manly J.J., Touradji P., Tang M.X., Stern Y. Literacy and memory decline among ethnically diverse elders. J. Clin. Exp. Neuropsychol. 2003, 25:680-690.
20. Manly J.J., Schupf N., Tang M.X., Stern Y. Cognitive decline and literacy among ethnically diverse elders. J.Geriatr. Psychiatry Neurol. 2005, 18:213-217.
21. Moghekar A., Goh J., Li M., Albert M., O'Brien R.J. Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort. Arch. Neurol. 2012, 69:246-250.
22. Monsell S.E., Mock C., Roe C.M., Ghoshal N., Morris J.C., Cairns N.J., Kukull W. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology 2013, 80:2121-2129.
23. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
24. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
25. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131.
26. Nelson H.E. The National Adult Reading Test (NART): Test Manual 1982, Nfer-Nelson, Windsor, UK.
27. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2009, 106:6820-6825.
28. Rentz D.M., Amariglio R.E., Becker J.A., Frey M., Olson L.E., Frishe K., Carmasin J., Maye J.E., Johnson K.A., Sperling R.A. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 2011, 49:2776-2783.
29. Rentz D.M., Locascio J.J., Becker J.A., Moran E.K., Eng E., Buckner R.L., Sperling R.A., Johnson K.A. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 2010, 67:353-364.
30. Resnick S.M., Sojkova J., Zhou Y., An Y., Ye W., Holt D.P., Dannals R.F., Mathis C.A., Klunk W.E., Ferrucci L., Kraut M.A., Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010, 74:807-815.
31. Roe C.M., Fagan A.M., Grant E.A., Marcus D.S., Benzinger T.L., Mintun M.A., Holtzman D.M., Morris J.C. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch. Neurol. 2011, 68:1145-1151.
32. Roe C.M., Fagan A.M., Williams M.M., Ghoshal N., Aeschleman M., Grant E.A., Marcus D.S., Mintun M.A., Holtzman D.M., Morris J.C. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011, 76:501-510.
33. Roe C.M., Mintun M.A., D'Angelo G., Xiong C., Grant E.A., Morris J.C. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch. Neurol. 2008, 65:1467-1471.
34. Roe C.M., Xiong C., Miller J.P., Cairns N.J., Morris J.C. Interaction of neuritic plaques and education predicts dementia. Alzheimer Dis. Assoc. Disord. 2008, 22:188-193.
35. Rolstad S., Nordlund A., Eckerstrom C., Gustavsson M.H., Zetterberg H., Wallin A. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment-proof of concept. Dement. Geriatr. Cogn. Disord. 2009, 27:194-200.
36. Rolstad S., Nordlund A., Eckerstrom C., Gustavsson M.H., Zetterberg H., Wallin A. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia-a follow-up report. Dement. Geriatr. Cogn. Disord. 2009, 28:110-115.
37. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
38. Scarmeas N., Levy G., Tang M.X., Manly J., Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 2001, 57:2236-2242.
39. Siedlecki K.L., Stern Y., Reuben A., Sacco R.L., Elkind M.S., Wright C.B. Construct validity of cognitive reserve in a multiethnic cohort: the Northern Manhattan Study. J.Int. Neuropsychol. Soc. 2009, 15:558-569.
40. Sole-Padulles C., Llado A., Bartres-Faz D., Fortea J., Sanchez-Valle R., Bosch B., Antonell A., Molinuevo J.L., Rami L. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res. 2011, 192:140-146.
41. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
42. Stern Y. Elaborating a hypothetical concept: comments on the special series on cognitive reserve. J.Int. Neuropsychol. Soc. 2009, 17:639-642.
43. Stern Y., Gurland B., Tatemichi T.K., Tang M.X., Wilder D., Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994, 271:1004-1010.
44. Vemuri P., Weigand S.D., Przybelski S.A., Knopman D.S., Smith G.E., Trojanowski J.Q., Shaw L.M., Decarli C.S., Carmichael O., Bernstein M.A., Aisen P.S., Weiner M., Petersen R.C., Jack C.R. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 2011, 134:1479-1492.
45. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
46. Wang M.C., Brookmeyer R., Jewell N.P. Statistical models for prevalent cohort data. Biometrics 1993, 49:1-11.
47. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual 1981, The Psychological Corporation, New York.
48. Wilson R.S., Mendes De Leon C.F., Barnes L.L., Schneider J.A., Bienias J.L., Evans D.A., Bennett D.A. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002, 287:742-748.
49. Yaffe K., Weston A., Graff-Radford N.R., Satterfield S., Simonsick E.M., Younkin S.G., Younkin L.H., Kuller L., Ayonayon H.N., Ding J., Harris T.B. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011, 305:261-266.
50. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J.Psychiatr. Res. 1982, 17:37-49.